In 110 Chinese patients with untreated extensive-stage SCLC, adding tiragolumab to atezolizumab plus carboplatin–etoposide gave median PFS 5.6 vs 5.4 months (HR 0.65) and median OS 18.7 vs 13.5 months (HR 0.89, CI 0.56–1.40); the global study was not significant.
RCTn = 110
Lu et al. SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China